OncoMatch/Clinical Trials/NCT07051486
A Phase II Trial of SHR-A1811 in HER2-Expressing Recurrent/Metastatic Cervical Cancer
Is NCT07051486 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies SHR-A1811 for recurrent or metastatic cervical cancer.
Treatment: SHR-A1811 — This study is a single-arm, multicenter Phase II clinical trial of SHR-A1811 for injection in patients with HER2-expressing recurrent or metastatic cervical cancer who have failed prior systemic therapy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Cervical Cancer
Biomarker criteria
Required: HER2 (ERBB2) expression (HER2-expressing)
HER2-Expressing Recurrent/Metastatic Cervical Cancer
Disease stage
Metastatic disease required
Lab requirements
Blood counts
Normal function of important organs
Kidney function
Normal function of important organs
Liver function
Normal function of important organs
Cardiac function
Normal function of important organs
Normal function of important organs
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify